See the snippet of an article below from Ben Finlay from Publicis Health. I like the fact that Conneqt clearly made an impact at CES2023 and we continue to get coverage .
I've been trying to find what impact Omron had at CES2023. Omron went big, taking out one of the major sponsorship's in CES2023, booking one of the pre-market press events and allocating a key-note speaker. For Omron it was all about unveiling a new UK remote patient-monitoring service to realize its "Going for Zero" goal vision to eliminate heart attack and stroke. The focus of Omron was on Atrial Fibrillation (AFib), one of the growing types of arrhythmias, and introduces a range of efforts to detect early AFib.
Despite all this, and I know I'm biased, when it comes to cardiovascular disease & hypertension, I do not believe they created any of the excitement and buzz that CardieX achieved. I haven't seen a single unpaid article pick up on Omron.
They may want to review how they approach CES2024 ... but good luck beating the buzz CardieX will create around Conneqt Band.
,,,,
CES23: Nine noteworthy Health disruptors
https://medium.com/@benfin/ces23-nine-noteworthy-health-disruptors-9a21caf85a7f
by Ben Finlay , Chief Innovation Officer at Publicis Health, board advisor for M&A and new health ventures.
3. Conneqt
Next-generation cuff-based vascular biomarker monitor, measuring standard systolic and diastolic blood pressure alongside clinically relevant biomarkers signalling heart health and other major organs. Potential application for patients enrolled in decentralised clinical trials, increasing patient retention using remote “anywhere” visit data collection, and decreasing patient adverse events by monitoring unique safety protocol endpoints. Conneqt offer ‘true personal insights’ and ‘complete vascular biometric analysis’ all through a very compact cuff design and decent looking digital experience.Origin: California, USA CEO: Craig Cooper conneqthealth.com
Add to My Watchlist
What is My Watchlist?
